Treats thrombocytopenia. Sold as Nplate. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Romiplostim (sold as Nplate), first approved Aug 22, 2008, with 3 new uses approved and 0 published complete response letters.
| NPLATE | Part B | $429M | New | 7,737 |
| NPlate | Part D | $20.6M | +17% | 327 |
| NPlate | Part B | $0K | -100% | 0 |
| Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell TransplantationHematologic Diseases · Liping Dou | Phase 2 | Recruiting | Nov 5, 2026 |
| Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsAnemia Associated With Chronic Kidney Disease · Chinese University of Hong Kong | Phase 2 | Recruiting | Oct 2, 2026 |
| Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell TransplantationThrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation · The First Affiliated Hospital of Henan University of Science and Technology | Phase 2 | Not yet recruiting | Sep 21, 2026 |
| Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast CancerThrombocytopenia Chemotherapy Induced · Fudan University | Phase 2 | Not yet recruiting | Aug 18, 2026 |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia · Amgen | Phase 3 | Recruiting | Jul 13, 2026 |
| Atorvastatin Combined With NAC Plus Romiplostim for Management of ITPImmune Thrombocytopenic Purpura · Peking University People's Hospital | Not applicable | Not yet recruiting | Jun 23, 2026 |
| Romiplostim for Oral TPO-RA Resistant ITPImmune (Idiopathic) Thrombocytopenic Purpura (ITP) · The First Affiliated Hospital of Soochow University | Not applicable | Recruiting | May 28, 2026 |
| A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related ThrombocytopeniaSepsis · Shanghai 10th People's Hospital | Phase 1 | Not yet recruiting | May 19, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Amgen